Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1959 1
1960 1
1961 1
1962 2
1963 6
1964 4
1965 3
1966 5
1967 2
1968 4
1969 7
1970 4
1971 3
1972 7
1973 5
1974 7
1975 8
1976 5
1977 3
1978 4
1979 4
1980 3
1981 4
1982 5
1983 5
1984 3
1985 5
1986 10
1987 5
1988 5
1989 5
1990 8
1991 2
1992 3
1993 5
1994 1
1995 3
1996 2
1997 1
1998 2
2000 2
2001 1
2004 1
2005 3
2006 3
2008 1
2009 1
2010 5
2011 2
2012 2
2013 3
2014 4
2015 3
2016 7
2017 7
2018 2
2019 6
2020 9
2021 11
2022 11
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
[Tumor-related pathological fractures].
Omar M, Ivanyi P. Omar M, et al. Among authors: ivanyi p. Unfallchirurg. 2021 Sep;124(9):685-686. doi: 10.1007/s00113-021-01043-1. Epub 2021 Aug 26. Unfallchirurg. 2021. PMID: 34448883 German. No abstract available.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Bevacizumab-associated glomerular microangiopathy.
Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, Schmitz J, Schwarz A, Ivanyi P, Steinmetz OM, Reinhard L, Hoxha E, Zipfel PF, Bräsen JH, Wiech T. Person F, et al. Among authors: ivanyi p. Mod Pathol. 2019 May;32(5):684-700. doi: 10.1038/s41379-018-0186-4. Epub 2018 Dec 14. Mod Pathol. 2019. PMID: 30552416 Free article.
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. Zschäbitz S, et al. Among authors: ivanyi p. Eur Urol Open Sci. 2023 May 17;53:31-37. doi: 10.1016/j.euros.2023.04.018. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37441344 Free PMC article.
[c-MET Oncogene in Renal Cell Carcinomas].
Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S. Erlmeier F, et al. Among authors: ivanyi p. Aktuelle Urol. 2016 Dec;47(6):475-479. doi: 10.1055/s-0042-115401. Epub 2016 Dec 22. Aktuelle Urol. 2016. PMID: 28006830 Review. German.
[Oncologic aspects in treatment of pathologic fractures].
Eggers H, Wichmann J, Omar M, Länger F, Ivanyi P. Eggers H, et al. Among authors: ivanyi p. Unfallchirurg. 2021 Sep;124(9):731-737. doi: 10.1007/s00113-021-01051-1. Epub 2021 Jul 13. Unfallchirurg. 2021. PMID: 34255103 Review. German.
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF, Achterfeld J, Sandner N, Koch C, Wiegmann JP, Ivanyi P, Käsmann L, Pusch R, Wolf D, Chirica M, Knösel T, Demes MC, Kumbrink J, Vogl TJ, Meyer G, Spitzweg C, Bojunga J, Kroiss M. Koehler VF, et al. Among authors: ivanyi p. J Cancer Res Clin Oncol. 2023 Nov;149(15):14035-14043. doi: 10.1007/s00432-023-05134-x. Epub 2023 Aug 7. J Cancer Res Clin Oncol. 2023. PMID: 37548775 Free PMC article.
Dysfunction of HLA-B27.
Ivanyi P. Ivanyi P. Scand J Rheumatol Suppl. 1990;87:51-69; discussion 69. doi: 10.3109/03009749009097058. Scand J Rheumatol Suppl. 1990. PMID: 2259889 Review.
Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity.
Möhn N, Mahjoub S, Duzzi L, Narten E, Grote-Levi L, Körner G, Seeliger T, Beutel G, Bollmann BA, Wirth T, Huss A, Tumani H, Grimmelmann I, Gutzmer R, Ivanyi P, Skripuletz T; ICOG-CCCH (Immune Cooperative Oncology Group; Comprehensive Cancer Center Hannover). Möhn N, et al. Among authors: ivanyi p. Cancer Med. 2023 Apr;12(8):9373-9383. doi: 10.1002/cam4.5695. Epub 2023 Feb 16. Cancer Med. 2023. PMID: 36794673 Free PMC article.
249 results